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‘Biomaterials  are defined as non-living materials able to replace a part of the human 
body’ 
 
Life expectancy is now over 80 years. This increase in survivability however, means 
that many people outlive the quality of their connective tissues and the capacity of human 
body to regenerate bony components that are lost or damaged is limited. Some 30 years ago, a 
revolution in medical care began with the successful replacement of tissues. Consequently, we 
have to find or to develop implants that might replace bony tissues. Two types of implants can 
be used : natural or synthetic [1]. 
The natural implants concern xenogenous, allogenous and autogenous bone grafts.  
Xenogenous bone grafts are implants which are coming from another species. Allogenous 
bone grafts are implants which are coming from the same species. However, many problems 
were generally associated with them such as in vivo resorption, virus transfer, considerable 
care, high costs and regular provocation of an immunological-defensive reaction, which limits 
their efficiency. Autogenous bone grafts are implants which are coming from the same body. 
These grafts are the most suitable because there is an excellent biocompatibility and no risk of 
transferring virus. However, removal of the bone grafts creates additional surgical trauma and 
its supply may not be available in sufficient quantity. To overcome all these problems, we 
have to find and to develop synthetic materials which might be used as bone substitutes or as 
prosthesis [2]. 
The second possibility in the revolution to replace tissues was the development, or in 
many cases modification, of man-made materials to interface with living, host tissues. These 
synthetic implants are called biomaterials. The significant advantages of synthetic implants 
over natural implants are availability, reproducibility and reliability. Good manufacturing 
practise, international standards, government regulations and quality assurance testing 
minimise the risk of failure of implants. However, implants developed actually have serious 
disadvantages : problems of interfacial stability with host tissues, low mechanical properties, 
production of wear particles. These problems limits bio-integration of implants and their 
lifetimes. Efforts to improve properties of implants have to be done. 
Actually, a lot of synthetic bone substitutes and prosthesis are available to repair bony 
tissues that are lost or damaged. The most widely used are polymers, metallic alloys 
(Ti6Al4V, Co-Cr, inox, …) and bioceramics (alumina (Al2O3), zirconia (ZrO2), calcium 
phosphates, bioactive glasses, biovitroceramics) [3] [4]. The ultimate goal of these materials 
is to reach full integration of the non-living implant with living bone. With advances in 
ceramic technology, the application of calcium phosphate materials, bioactive glasses and 
biovitroceramics as bone substitutes or as coatings on prosthesis has received considerable 
attention, because they are highly biocompatible (well accepted in biological environment) 
and they have bioactive properties [5] [6] [7]. These materials are capable, through physico-
chemical reactions, to establish a direct contact with bone [8]. However, many critical and 
complex reactions take place at the implant/bone tissues interface [9]. Structural and chemical 
evaluation of this interface is primordial to determine the success of an implant. Elemental 
composition and surface properties play a very important role in these reactions [10]. 
Knowledge of the elemental distribution at the biomaterials/bone tissues interface is important 
to understand the physico-chemical mechanisms involved during the material integration and 
bone bonding [11] [12].  
 
2. Analysis of biomaterials interfaces 
Structural and chemical evaluation of biomaterials/bone interfaces requires analysis at 
the nanometer level. Transmission electron microscopy (TEM), energy dispersive X-ray 
spectroscopy (EDXS), electron energy loss spectroscopy (EELS) are methods which permits 
this analysis at the required resolution. TEM and associated techniques are powerful tools 
which can provide chemical and physical information : interlayer thickness, chemical species, 
local bonding, and the nature of crystalline or amorphous products [13] [14]. On the other 
hand, complementary techniques like PIXE (Particles induced X-ray emission), SIMS 
(Secondary ion mass spectrometry) and AFM (atomic force microscopy) are useful to better 
evaluate biomaterials/ bone tissues interface. 
 
2.1 TEM 
Development of transmission electron microscopy (TEM) permits to obtain 
morphological and chemical information at the nanometer scale from the sample examined. 
Different types of interactions can occur between incident electrons and the sample. The 
majority of incident electrons are transmitted, elastically diffused and inelastically diffused. 
Electrons are not diffused when incident electrons are transmitted without any interaction 
with the specimen. This phenomenon increases when the specimen thickness decreases. 
Electrons diffused elastically are electrons which are diffused by the electromagnetic field 
created by nucleus of atoms. During this interaction, they loss a very low amount of energy of 
the order of some eV. This diffusion is called elastic diffusion because there is no energy 
transferred. Electrons diffused inelastically loss energy during collisions with electrons from 
atoms of the sample. This energy loss is characteristic from the atoms with which this 
interaction occurs. Several other signals can be generated after electron beam-sample 
interactions : secondary electrons emission, backscattering of incident electrons, 
cathodoluminescence, Auger electrons emission, X-ray emission. Secondary electrons are 
electrons ejected from the conduction band because of their low bonding energy. Their 
kinetics energy is of the order of 50 eV. These electrons give a topographic information of the 
surface. Backscattered electrons are electrons which pass near nucleus of atoms and are 
backscattered by the electromagnetic field of the nucleus. Cathodoluminescence represents 
photons which have a wave length between 0.4 – 0.8 µm (visible). These photons are emitted 
by materials like semi-conductors, organic molecules during the irradiation by the electron 
beam. Moreover, the interaction between the high energy electrons from the beam and atoms 
from the sample lead to the atoms ionisation. Electrons from the inner shells of atoms are 
ejected from their orbits, leaving the inner shells incompletely filled. This gap is filled by an 
electron from outer shells. This transition can lead to an X-ray photon emission, with an 
energy equal to the energy difference between the two shells or to the emission of an electron 
from outer shells : Auger electron.  
Morphological, structural information can be obtained by contrasted images of 
transmitted electrons [15]. Chemical information can be obtained from the electron beam-
sample interaction [15] [16]. Two of the signals generated are X-ray signal (which is used in 
Energy Dispersive X-ray Spectroscopy, EDXS)  and electron energy loss signal issued from 
electrons diffused inelastically (which is used in Electron Energy Loss Spectroscopy, EELS). 
These two spectrometries are used to obtain elemental and eventually chemical information. 
EDXS is now well developed and allows the elemental analysis of all elements with Z>5. 
This technique permits quantitative elemental analysis, concentrations profiles and elemental 
cartographies with a resolution of the order of 10 nm [17]. The minimal detectable 
concentration is of the order of 500 ppm. EDXS allows the elemental analysis of biomaterials-
tissues interface together with the study of its ultrastructure in transmission electron 





 The X-ray energy is characteristic of the element in which the electronic transition 
occurred and permits to determine the elements present in the sample [20]. Atoms are 
composed with many shells and many transition can take place [21]. The K-line correspond to 
an X-ray generated after the ionisation of the K-shell, the L-line correspond to an X-ray 
generated after the ionisation of the L shell, and so on [22]. For example, a transition from LIII 
to K is designated Kα1 and from MV to LIII is designated Lα1. Transitions do not occur with the 
same probability. The most intense in each series are the α1.  Considering the same line (Kα1 
for example) the X-rays energy increases with the atomic number. In an atom, the K lines 
have a lower energy than L lines and the L lines have a lower energy than the M lines.   
On the other hand, the incident electron beam can be inelastically scattered by 
electromagnetic field of the nucleus of atoms in the sample. The energy loss by the electron 
leads to an X-ray emission of corresponding energy which is called continuum or background 
[23]. This background do not permit to determine the elements present in the sample. 
However, its intensity is proportional to the mass of the analysed volume and can be used for 
quantitative calculations [24].  
 
2.2.1 Instruments 
A transmission electron microscope generates the electron beam and gives the 
ultrastructural information about the sample. The electron beam size is very important to 
obtain an optimal spatial resolution. Actually, scanning transmission electron microscope 
(STEM) permits to obtain a resolution under 1 nm. The X-rays generated in the specimen by 
the electron beam are collected by a semi-conductor detector, amplified and displayed with a 
multichannel analyser associated to a computer. Spectrum is displayed and stored. 
The type of detector usually used is a lithium drifted silicon semiconductor detector 
(in short Si(Li) detector) cooled to liquid nitrogen temperature. The resolution of a detector is 
defined as the full width half-maximal height (FWHM) of the Mn Kα peak which is at an 
energy of 5.9 keV [25]. Actually, resolution is of the order of 140 eV. This type of detectors 
are protected from contamination from the microscope by a beryllium entrance window of 8 
µm in thickness. However, this window absorbs low energy X-rays which limits the detection 
to elements heavier than Na (Z>11). Recently the developments of these detectors with an 
ultrathin window or window less permit the analysis of all elements down to boron. 
The spectrum is composed with characteristic X-ray peaks for various elements and 
background (Figure 1). We can observed the presence of carbon (C Kα), oxygen (O Kα), 
copper (Cu Lα , Cu Kα , Cu Kβ), sodium (Na Kα), silicon (Si Kα), phosphorus (P Kα) and 
calcium (Ca Kα , Ca Kβ). Spectral lines like α1 and α2 (respectively β1 and β2) are so close 
to each other that they cannot be resolved by the spectrometer, and the convoluted line is 
simply denoted α (respectively β). 
 
2.2.2 Quantitative analysis 
Calculations of elemental concentrations are made in the computer. The quantitative 
analysis of a specimen links the characteristic X-ray intensity to the number of atoms which 
emit this characteristic X-ray. Two methods can be used to calculate concentrations : the Hall 
method [26][27][28] and the Cliff&Lorimer method [29]. In the first method, Hall proposed 
an alternative approach in which the mass of the matrix is measured from the intensity of the 
background. The concentration of an element is proportional to the peak intensity/background 
intensity ratio. By using standards, this method permits to quantify elemental concentrations 
without the detection of all elements. Concentrations are determined separately from each 
other.  This method can be used with all types of detectors, even those with a beryllium 
entrance window. However, this method has a serious disadvantage. The background of the 
specimen is superposed to the background of the grid support. This contribution varies with 
the distance between the analysed zone and the nearest bar of the grid. In order to minimize  
errors induced by this phenomenon, measurements must be done as far as possible from the 
bars of the grid. The second method does not use the background intensity. This method is 
based on the fact that the sum of all elemental concentrations (weight %) in the specimen is 
equal to unity. Then, the elemental concentration of each element can be calculated. However, 
this method need the correct detection of all elements present in the sample and especially 
light elements which are highly present in biological specimens. Detectors with a beryllium 
window entrance can not be used. 
 
2.2.3 Samples preparations 
For STEM and EDXS analysis at the nanometer scale the sample preparation is 
crucial. Several problems must be solved [30] [31]. 
 • Ultrathin sections under 500 nm of the biomaterials-tissues interface must be 
prepared to perform the analysis at the resolution required. This is a very difficult step 
because the interface between hard materials and soft tissues must be in the sections. 
 • The specimen support should not contain elements of interest present in the studied 
sample. 
• The preparation method must not change the chemical identity of the specimen. If 
the elements of interest in the sample are not firmly bond, they can be solubilized during 
preparation [32]. 
Actually two preparation methods can be distinguished. 
 
 
a Conventional preparation method  
Biological ultrathin sections are prepared by a process including different steps [33]: 
• Fixation in aldehyde. 
• Post-fixation in osmium (osmium tetroxide, OsO4 ). 
• Dehydration in increasing concentrations of alcohol.  
• Embedding in resin.  
• Sectioning with an ultramicrotome. 
• Section staining with uranyl acetate and lead citrate. 
• Carbon (C) or gold sputtering (Au).  
This method allows a very good identification of the ultrastructure at the biomaterials-tissues 
interface [34] [35]. However, this preparation has disadvantages. Only firmly bond elements 
can be analysed. During fixation, the diffusible ions (Na, K, Cl, Mg, Ca) present in tissues and 
materials are lost from the sample [36]. During preparation, use of osmium, uranyl acetate and 
lead citrate adds Os, U and Pb in the sample. X-rays of these elements may interfere with X-
rays of elements of interest in the sample. The gold sputtered may interfere too. Finally, 
chloride can be added to the sample by the resin. Table 1 summarises different types of 
interferences which can be generated by the sample preparation. For example, copper found in 
spectrum in figure 1 comes from the grid and copper is not present in the specimen. 
 
b Cryopreparation methods  
 Various methods for cryopreparation are available. The first step consist of a rapid 
freezing of the specimen by liquid ethane cooled by liquid nitrogen (-196°C) or a metal 
cooled by liquid nitrogen [37] [38]. The high speed reduces considerably the formation of ice 
crystals. Then, cryosections are made with an ultracryomicrotome at a temperature of the 
order of –140°C. Then, two types of analysis are possible : 
• The sections are transferred in the microscope in the frozen-hydrated state 
and they can be studied in this state [39] [40] [41] [42] [43].  
• The sections can be freeze dried in the microscope chamber or they can be 
freeze dried and transferred in the microscope at the room temperature for the analysis 
[38].  
Other techniques including freeze-drying, freeze substitution, then infiltration by resin and, 
finally sectioning can be used [44] [45].       
 These methods permit to retain all elements of interest at their in vivo or in vitro 
position [46] [47]. They allow to study ion distribution and ion diffusion in biomaterials 
during their interaction with tissues or in cells in contact with biomaterials [48]. Analysis is 
performed in a state near the in vivo or in vitro state. 
 
 2.3 EELS 
EDXS is very useful for elemental analysis, but this technique is limited with its 
spatial resolution of analysis and its sensitivity. Electron Energy loss Spectroscopy (EELS) 
appears as a good complementary technique [49]. Its spatial resolution is of the order of the 
nanometer and the minimal detectable concentration in the order of 400-500 ppm. During 
ionisation of atoms present in the sample, electrons loss a certain amount of energy which is 
specific for the atoms that is ionised. Detection of energy loss by the electrons that have 
passed through the sample permits to determine the elemental composition and even fine 
structures. Sensitivity of this method for light elements is better than that of EDXS. 
Unfortunately, the sample must be very thin (less than 100 nm). The use of EELS is very 
limited for the study of biomaterials by the difficulty in preparing sufficiently thin sections.  
  
 
2.4 SAED and HRTEM 
 High resolution transmission electron microscope (HRTEM) and electron diffraction 
mode, including selected-area electron diffraction (SAED) and microdiffraction permit to 
determine the crystalline character of a part of the studied specimens [50]. Electron beam of 
some nanometers in diameter are used to determine the crystalline structure. Materials are 
assessed as ‘amorphous’ when electron diffraction patterns show broad and diffuse ring 
patterns and when there is no visible speckle in the rings. Crystalline materials give spotty 
diffraction patterns or spotty ring patterns. Finally, patterns analysis and calculations allow to 
determine distances between atomic plans and the crystalline structure at the nanometer scale. 
 
2.5 PIXE 
Protons are charged particles which can generate characteristic X-rays in the same way 
as electrons do. Particles induced X-ray emission (PIXE) method used 3 MeV energy proton 
beam to ionise atoms. This technique is used for trace element analysis because the peak to 
background ratio is much better than in EDXS [51]. The limit of detection of PIXE is several 
ppm. A further very important advantage is that PIXE can be used as a micro-beam technique, 
which allows elemental mapping with a good spatial resolution.  However, a proton beam can 
not be as finely focussed as an electron beam. Last instrumental developments permit to 
obtain proton beams in the order of 200-400 nm. This method is interesting to study trace 
elements locally at biomaterials interface.      
  
 2.6 SIMS 
Secondary ion mass spectrometry (SIMS) is used to analyse the surface composition 
and eventually a depth profile can be obtained because several layers are sputtered away. An 
ion beam is used to generate secondary ions from the surface specimen. The sensitivity of this 
method is of the order of 1 ppm and its resolution is near 100 nm. 
  
2.7 AFM 
During the last decade, developments of atomic force microscopy (AFM) permits to 
characterize the local properties of covered surfaces, namely the degree of coverage, the 
thickness of the layer and the shape [52]. Interactions between a tip (cantilever) and 
specimens surface permit to obtain images of surface structures at the nanometer scale. AFM 
has become a common experimental method in the investigation of biomaterials during the 
past 10 years [53], even if it is a delicate technique for measurements of soft materials as well 
as for evaluation and interpretation. This method allows to determine adsorption of proteins 
on materials, surface rugosities induced by protein adsorption. Concerning bioactive 
materials, AFM is used to study changes of surface morphology and roughness during 
bioactivity process. The structure of the apatite layer and the size of apatite crystals can be 
studied during interactions between bioactive materials and biological fluids [54] [55]. 
 
3. Physicochemical reactions at biomaterials interface 
3.1 Biomaterials used to replace bony tissues 
Actually, various types of biomaterials are used in orthopaedic and maxillo-facial 
surgery.  These materials can generate different reactions at the implant/bone interface and 
can be separated into three categories : bio-tolerant materials, bio-inert  materials and 




 3.1.1 Bio-tolerant materials  
Bio-tolerant materials are materials which are incorporated in bony tissues but with 
interposition of a layer of fibrous tissues between the materials and bone. For example, 
polymethyl methacrylate and cobalt-chrome (Co-Cr) alloy. The distance between the 
materials and bone is in the order of 1-20 µm [60]. The presence of the fibrous layer can lead 
to micro-movements of the implant, to corrosion and to the release of wear debris, which 
limits long-term stability. 
 
3.1.2 Bio-inert materials 
Bio-inert materials are materials which are in contact with bone without leading to low 
tissues reactions and formation of a fibrous layer. For example : alumina (Al2O3), zirconia 
(ZrO2), Titanium alloys [60]. However, there is no intimate or chemical contacts between 
bone and implants. These materials are poorly degraded by the surrounding tissues and well 
accepted by the biological environment. Unfortunately, sometimes wear debris are released, 
which limits the efficiency of the implants and its long-term stability.  
 
3.1.3 Bioactive materials   
Bioactive materials are defined by Hench [61] as materials capable to create a 
chemical bond with surrounding tissues without interposition of a fibrous layer. This 
phenomenon leads to an intimate link between bone and materials. Two kinds of bioactive 
materials can be defined : resorbable materials and surface reactive materials. 
 
 After implantation in bony tissues, the materials is progressively resorbed by bone 
cells (macrophages, osteoclasts), degraded by a chemical dissolution and finally replaced by 
bone [62]. Materials resorption and bone formation occurs simultaneously in order to have a 
stability of the bone/materials interface [63]. The fixation of these implants is called 
‘biological fixation’ with a porous ingrowth. These materials exhibit osteoconductive 
properties, defined as the characteristic of bone growth in porosities and bonding along the 
surface. Having the same chemical composition as natural bone, the calcium phosphate 
ceramics [64] (table 2) and calcium carbonates (CaCO3, coral) [65] are resorbable. 
 The dissolution process is highly dependant of the porosity, the crystalline structure 
and the degree of crystallinity [66]. Calcium phosphate ceramics with macroporosities (300-
400 µm) are more resorbable than calcium phosphate ceramics with microporosities 
(<10µm)[67] [68]. A high crystallinity degree reduces the resorbability of calcium phosphates 
[69]. On the other hand, it is interesting to note that some polymers are resorbable. However, 
mechanisms of their degradation/resorption and biological effects of their degradation 
products are not well known.    
 
 During the last decade, considerable attention has been directed towards use of 
bioactive fixation of implants. The most bioactive materials are bioactive glasses, 
biovitroceramics, hydroxyapatites (Ca10(PO4)6(OH)2) and composite materials 
(hydroxyapatite-tricalcium phosphate, …). At the interface between these materials and bone 
tissues a direct chemical bond is formed through a biological active apatite (Ca, P) layer [70] 
[71] [72]. This chemical reaction is the bioactivity property. An important advantage of 
bioactive fixation is that a bioactive bond to bone has a strength equal or greater than bone 
after 3 months. A bioactive bond to collagen fibrils of soft connective tissues is stronger than 
the cohesive bond of collagen fibrils. This high strength of both hard and soft tissues bonding 
to bioactive implants comes from the in vivo growth of an apatite layer of nanometer scale 
which bind to collagen fibrils [8]. 
 
3.2 Bioactivity process 
The bioactivity process differs with the type of materials, their composition and 
structure. We can distinguish four types of bioactivity process. 
3.2.1 Bioactivity process of bioactive glasses 
 In 1970, Hench  [10] [73] discovers the bioactive glasses. They are amorphous 
materials with low mechanical properties which reduces their applications to prosthetic 
coatings [74] [75] and to fill bony defects [76] [77] [78] [79]. The particular composition 
which initiates bioactivity is based on four oxides : (45%) SiO2, (24.5%) CaO, (24.5%) Na2O 
and (6%) P2O5. The bioactivity properties of these materials depend on the percentage of 
these three oxides : SiO2, CaO, Na2O. An increase of SiO2 considerably reduces the 
bioactivity and a high increase leads to a bio-inert material [61]. An increase of CaO or Na2O 
leads to a non-glass material. In fact, a very limited range of bioactive glass compositions, 
containing SiO2-CaO-Na2O-P2O5, that have less than 55% SiO2 exhibit a high bioactivity and 
bond to both bone and soft connective tissues [80][81]. Bioactive glasses can be obtain by 
melting the components at 1350°C or by sol-gel method at a lower temperature [82]. The 
synthesis of bioactive glasses by sol-gel process was proposed in the last decade [83] [84]. 
The solutions to obtain bioactive gel-glasses were prepared from stoichiometric amounts of 
tetraethoxysilane, triethyl phosphate and Ca(NO3)2.4H2O. Hydrolysis and condensation at low 
temperature create a highly interconnected 3-D gel network composed of (SiO4)
4- tetrahedral 
via bridging oxygen bonds or by Si-O-Ca or Si-O-P non-bridging bonds [85][86][87][88]. 
 The bioactivity process has been studied in vitro during interactions between bioactive 
glasses and biological fluids (table 3) or in vivo during interactions with bony tissues [12] [89] 
[90] [91] [92]. This process is decomposed in a complex series of physico-chemical reactions 
including, dissolution, diffusion, ionic exchange and precipitation (figure 2) [93] [94] [95] 
[96]: 
• Rapid exchange of alkali ions (Na+) with H+ or H3O
+ from surrounding fluids 
through an exchange layer of the order of 200 nm [14]. 
• Loss of soluble Si to the solution resulting from breaking of Si-O-Si bonds. 
Soluble silicon migrates toward the surface and there is formation of Si-OH and Si-
(OH)4 groups at the surface. The exchange process consist of a flow of H3O
+ ions and 
an equivalent flow of sodium ions into the solution from the glass represented as 
follow : 
SiO-Na+  + H3O
+  →  SiOH  +  H2O  +  Na
+  
Then, there is condensation and repolymerisation of a hydrated Si rich layer on the 
surface depleted in alkali and Ca,P elements. This layer is a vitreous gel [54]. 
• Migration of Ca and P from the glass to the surface of the Si layer. Several 
authors described this phenomenon as a diffusion process through the Si rich layer. 
• Growth of the vitreous gel by alkali exchange. 
• Precipitation of an apatite (Ca-P) rich layer on top of the Si layer.  
• Growth of the Ca-P rich layer. At the beginning the apatite crystals size is of 
the order of 200 nm and increases to some micrometers by consuming Ca2+, −34PO , 
CO3
-, −24HPO  from surrounding fluids. This layer incorpores collagen fibrils from 
surrounding tissues. 
 
  The formation of this apatite layer represents the bioactivity properties and permits a 
chemical link between the materials and the newly formed bone. The apatite crystals of the 
Ca-P layer and the apatite crystals of bone are intermingled each others which lead to a strong 
bonding [97]. Concerning bioactive gel-glasses, the 1-10 nm scale solid network of the gel is 
completely interpenetrated by pore liquid. The pore liquid consists of a highly structured 
hydrated layer with hydrated connective tissues. Biological molecules can exchange with 
these hydrated layers inside the pores and maintain their structure together with their 
biological properties [98] [99]. The nanometer sized pores of the gel glass are proposed to act 
as initiation sites for apatite nucleation [100]. 
 
STEM is able to show unambiguously the presence or absence of thin amorphous or 
crystalline films at interfaces. Figure 3 shows bioactive glass particles cultured with bone 
cells (osteoblasts) during two days. Interactions between bioactive glass particles and the 
culture medium lead to the materials dissolution, to the formation of Si layer and finally to the 
precipitation of an apatite layer. On the image, this layer appears as an electron dense layer. 
At this short time period, the apatite layer is of the order of 200 nm in thickness and its size 
will increases with time. In case of a crystallised apatite layer, a needle shape like structure 
will appear. EDXS spectrum on this layer demonstrate the presence of Ca and P elements 
[75]. The apatite layer acts as a template for bone cells adhesion and differenciation [91]. 
Figure 4 shows a bioactive glass coating/bone interface at 3 months. We clearly notice the 
presence of the bioactive glass coating in dissolution, the Si layer, the apatite layer and the 
newly formed bone. An intimate contact is observed between the glass and bone. Elemental 
profiles performed with EDXS permit to determine the exact composition of the different 
zones and their evolution with time. 
 
One of the main problems associated with the use of bioactive glasses as prosthetic 
coatings is high solubility, which might reduces the long-term stability of the glass. Extensive 
dissolution of the glass networks occurs within days. Optimisation of bioactive glasses 
properties concerns the compromise between bioactivity and solubility which is related to 
individual components [101] [102] [103] [104]. For example, addition of Al2O3 can be used to 
control the solubility of the glass. However, this addition may inhibit the bone bonding [105]. 
Greenspan and Hench demonstrate that a concentration of Al2O3 higher than 2% inhibits 
bioactivity [106].  
 
3.2.2 Bioactivity process of biovitroceramics 
A vitro ceramic is obtained by a temperature treatment of a glass in which nucleation 
factors are added in order to induce a partial or total crystallisation of this glass. This 
treatment increases mechanical properties of the glass. A biovitroceramics has a structure and 
a particular chemical composition which are crucial for the bioactivity properties. Three types 
of biovitroceramics are elaborated [107] [108] : 
• Biovitroceramics composed with a vitreous matrix ((16.6%) MgO, (24.2%) 
CaO, (59.2%) SiO2) in which apatite crystals (Ca10(PO4)6(O,F2) are incorporated.  
• Biovitroceramics (A-W) composed with a vitreous matrix in which apatite 
crystals and β-wollastonite crystals (CaSiO3) are incorporated. 
•  Biovitroceramics composed with a vitreous matrix in which apatite crystals, 
β-wollastonite crystals and whitelockite crystals (3CaOP2O5) are incorporated. 
 
 All these biovitroceramics contain apatite crystals which are important in the 
bioactivity process. Studies of the bioactivity was made in vitro during interactions between 
biovitroceramics and biological fluids, and in vivo during interactions between 
biovitroceramics and bone [108]  [109]. The bioactivity is based on (figure 5) : 
• Dissolution of the vitreous matrix, wollastonite crystals and whitelockite 
crystals (if they are incorporated). 
• Ionic release of HSiO3
-, Ca2+, Mg2+ at the surface.    
• Precipitation of an apatite layer by consuming Ca2+, −34PO , CO3
- and −24HPO  
from biological fluids. 
 The formation of this apatite layer at the surface of biovitroceramics occurs without 
the formation of a Si-rich layer [110] [111]. This layer of some micrometers in thickness 
permits a chemical bond between the materials and the newly formed bone. 
 
  3.2.3 Bioactivity process of hydroxyapatites 
 Synthetic hydroxyapatites are calcium phosphate ceramics elaborated under pressure 
and under temperature treatment of Ca(NO3)2, H3PO4, NH4OH and H2O [112]. This ceramic 
is used under different form : powders, bulk or as coatings. For example, figure 6 shows a 
STEM micrograph of nanostructures of hydroxyapatite powders. For bulk materials, various 
porosities are available [113]. We can distinguish microporosities (<10 µm) which permit 
diffusion of ions and fluids from macroporosities (100-600 µm) which permit cellular 
colonisation. The bioactivity process was studied in vitro and in vivo [114] [115] [116]. It 
occurs under an acidic attack with H+ at the material surface (figure 7) [117]. This leads to the 
dissolution of hydroxyapatite crystals and a high release of Ca2+, −34PO  [118] [119]. 
Concentration of calcium and phosphorus increase in the surrounding fluids and this 
supersaturation induces reprecipitation of apatite crystals at the ceramic surface [120]. These 
apatite crystals may incorporate Ca2+, Mg2+, CO3
-, −34PO and organic molecules present in the 
surrounding fluids [121] [122]. This dissolution-reprecipitation process leads to the formation 
of a carbonated apatite layer at the material surface and permits a chemical bond with newly 
formed bone [114]. This layer is in the order of  200-800 nm [123] [124] [125] [126]. 
Solubility of hydroxyapatites vary with different factors : porosity, grain size, crystallinity, 
sintering temperature [127] [128] [129] [130]. An increase of the sintering temperature leads 
to an increase of the hydroxyapatite crystals size and finally reduces its solubility. For 
example, hydroxyapatite treated at 600°C has crystals of 180 nm in size and  crystals of 350 
nm in size with a treatment at 1180°C [129]. On the other hand, the solubility increases with 
the porosity and pores size. 
 
3.2.4 Bioactive titanium 
 Recently, it has been found that even pure titania hydrogel prepared by sol-gel method 
induces apatite formation [72] [131] [132]. When titanium is treated by immersion in alkaline 
solution (NaOH), a hydrated titanium oxide gel layer containing alkali ions is formed on its 
surface. This gel layer is dehydrated and densified to form an amorphous alkali titanate (TiO2 
+ Na+) layer by heat treatment below 600°C. When the pre-treated titanium is exposed to 
biological fluids, the alkali ions are released from the amorphous alkali titanate layer and 
hydronium ions enter into the surface layer, resulting in the formation of a titanium oxide 
hydrogel layer. The released Na+ ions increase the degree of supersaturation of the soaking 
solution with respect to apatite by increasing pH, and titanium oxide hydrogel induces apatite 
nucleation on the titanium surface [133]. 
 
3.2.5 Apatite precipitation process 
Determination of crystals size, nucleation and growth of apatite during interactions 
with surrounding fluids is important to better understand dissolution-precipitation process 
during bioactivity [134]. The combination of HRTEM, SAED and nano probe electron 
diffraction allow to determine morphology and structure of apatite crystals size [135]. The 
crystals size vary from a few nanometers to a micrometer [136]. The increase of the apatite 
crystals size occurs as a result of lower supersaturation in crystallization system because of 
the absence of convection in space and the strong reduction in the rate of nucleation [137].  
In some cases, the apatite precipitates are amorphous. During apatite precipitation, 
some ions like Mg2+, CO3
- are able to enter the forming apatite nuclei and thus inhibit their 
evolution to tiny apatite crystals [138]. These phenomena can promote a greater dissolution of 
the newly formed apatite precipitates [139] [140] [141]. 
 
4. Conclusion 
 Structural and chemical evaluation of bioactive biomaterials/bone tissues interface 
requires analysis at the nanometer scale. Transmission electron microscopy and associated 
techniques enable the chemical and physical characterization of bioactive materials/bone 
tissues interfaces, providing information on interlayer thickness, chemical species, local 
bonding and the nanostructural features which give rise to the interfacial properties. Thereby 
enabling a full understanding not only of biomaterials after processing, but also after 
interactions with bone tissues [142]. 
 Bioactive materials are capable to bond directly to bone through an apatite layer. This 
intimate link results from simultaneous physico-chemical and biological processes. The 
bioactive materials in contact with bone tissues undergo dissolution with leaching and 
precipitation of apatite crystals occurs together with adsorption of organic compounds [143] 
[144]. Apatite crystals grow by epitaxial growth [145]. Simultaneously, bone cells 
mineralised an extracellular matrix on the materials composed with apatite crystals. Apatite 
crystals issued from the materials and apatite crystals issued from mineralisation are 
intermingled which lead to a strong bonding between implants and bone. This process of 
bioactivity occurs more rapidly in bioactive glasses and in biovitroceramics than in 
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Table 1 : Common extraneous peaks causing artefacts during analysis. 
 
Table 2 : Some calcium phosphates available actually. 
 
Table 3 : Ion concentrations (mmol.dm-3) of biological solutions used to study physico-
chemical reactions of bioactive materials. 
 
Extraneous peak Source Interferes with these 
elements 
Al Kα Specimen holder Br Lα 
Si Kα Contamination from microscope Sr Lα 
Cu Kα Grid Zn Kα , Os Lα 
Cu Lα Grid Na 
Pd Lα Coating Cl Kα 
Pd Lβ Coating K Kα 
Os Lα Postfixation Zn Kα 
Os Mα Postfixation P Kα 
Au Mα Coating P Kα , S Kα 
Pb Mα Section staining S Kα , Cl Kα 
U Mα Section staining K Kα 
   






Calcium phosphates (synthetic) Chemical formulae Ca/P 
Brushite, dicalcium phosphate dihydrate CaHPO4.H2O 1 
Monetite, dicalcium phosphate anhydrous CaHPO4 1 
Octacalcium phosphate, OCP Ca8H2(PO4)6.5H2O 1.33 
Tricalcium phosphate, β-TCP Ca3(PO4)2 1.5 
Calcium hydroxyapatite, HA Ca10(PO4)6(OH)2 1.67 
Calcium fluorapatite, FA Ca10(PO4)6F2 1.67 
Tetracalcium phosphate Ca4P2O9 2 
   
      Table 2 








Simulated body fluid, SBF 142 5 1.5 2.5 147.8 4.2 1 0.5 







Figure 1 : Spectrum showing characteristic peaks for various elements and the continuum 
(background). 
 
Figure 2 : Schematic view of the bioactive glass/bone interface during the bioactivity process. 
 
Figure 3 : STEM micrograph of bioactive glass particles immersed in a biological solution 
with bone cells (osteoblasts) during two days. The particles are in dissolution and an electron 
dense layer appears (apatite layer). These particles are engulfed in an organic matrix.  
 
Figure 4 : STEM micrograph of a bioactive glass coating/bone interface after 3 months  of 
implantation. The bioactive glass coating is in dissolution and firmly fixed to newly formed 
bone through an apatite layer on top of a pure Si layer. 
 
Figure 5 : Schematic view of the biovitroceramic/bone interface during the bioactivity 
process. 
 
Figure 6 : TEM micrograph showing nanostructures of hydroxyapatite particles. 
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